Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 306

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Results of autologous stem cell transplant in multiple myeloma patients with renal failure

Open access
Badros, Ashraf, Barlogie, Bart, Siegel, Eric, Roberts, Jennifer, Langmaid, Candi, Zangari, Maurizio, Desikan, Raman, Shaver, Mary Jo, Fassas, Athanasios, McConnell, Scott, Muwalla, Firas, Barri, Yousri, Anaissie, Elias, Munshi, Nikhil, Tricot, Guido·2001·British Journal of Haematology

Abstract

Data are presented on 81 multiple myeloma (MM) patients with renal failure (creatinine > 176·8 μmol/l) at the time of autologous stem cell transplantation (auto‐SCT), including 38 patients on dialysis. The median age was 53 years (range: 29–69) and 26% had received more than 12 months of prior chemotherapy. CD34+ cells were mobilized with granulocyte colony‐stimulating factor (G‐CSF) alone (n = 51) or chemotherapy plus G‐CSF (n = 27), yielding medians of 10 and 16 × 10 6 CD34+ cells/kg respectively (P = 0·003). Sixty patients (27 on dialysis) received melphalan 200 mg/m 2 (MEL‐200). Because of excessive toxicity, the subsequent 21 patients (11 on dialysis) received MEL 140 mg/m 2 (MEL‐140). Thirty‐one patients (38%) completed tandem auto‐SCT, including 11 on dialysis. Treatment‐related mortality (TRM) was 6% and 13% after the first and second auto‐SCT. Median times to absolute neutrophil count (ANC) > 0·5 × 10 9/l and to platelets > 50 × 10 9/l were 11 and 41 d respectively. Non‐haematological toxicities included mucositis, pneumonitis, dysrhythmias and encephalopathy. At a median follow up of 31 months, 30 patients have died. Complete remission (CR) was achieved in 21 patients (26%) after first SCT and 31 patients (38%) after tandem SCT. Two patients discontinued dialysis after SCT. Median durations of complete remission (CR) and overall survival (OS) have not been reached; probabilities of event‐free survival (EFS) and OS at 3 years were 48% and 55% respectively. Dialysis dependence and MEL dose did not affect EFS or OS. Sensitive disease prior to SCT, normal albumin level and younger age were independent prognostic factors for better OS. In conclusion, renal failure had no impact on the quality of stem cell collections and did not affect engraftment. MEL‐140 had an acceptable toxicity and appeared equally effective as MEL‐200. In the setting of renal failure, the role of auto‐SCT early in the disease course and benefits of tandem SCT require further evaluation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2141.2001.03033.x

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 306

Metadata

Authors
Badros, A., Barlogie, B., Siegel, E., Roberts, J., Langmaid, C., Zangari, M., Desikan, R., Shaver, M. J., Fassas, A., McConnell, S., Muwalla, F., Barri, Y., Anaissie, E., Munshi, N., & Tricot, G.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2001-09
Volume
114
Issue
4
Pages
822-829
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2135455274
Cited by
306
References
16
FWCI
6.02
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results of autologous stem cell transplant in multiple myeloma patients with renal failure. https://app.cochat.ai/papers/10.1046/j.1365-2141.2001.03033.x
The paper
Badros, A., Barlogie, B., Siegel, E., Roberts, J., Langmaid, C., Zangari, M., Desikan, R., Shaver, M. J., Fassas, A., McConnell, S., Muwalla, F., Barri, Y., Anaissie, E., Munshi, N., & Tricot, G. (2001). Results of autologous stem cell transplant in multiple myeloma patients with renal failure. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2001.03033.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.